MRV Research

NYU Langone’s Laura and Isaac Perlmutter Cancer Center and Technion-Israel Institute of Technology Launch Global Research Initiative

MRV Research

Newswise — (New York, NY and Haifa, Israel, April 21, 2016) – Drug-carrying “nanoghosts” that battle melanoma and new treatments for malignant mesothelioma will be the focus of the first joint research projects led by NYU Langone Medical Center and the Technion-Israel Institute of Technology under a groundbreaking research initiative supported by noted philanthropists and NYU Langone Trustees Laura and Isaac Perlmutter.

Read More

Aging Influences Melanoma Response to Therapies, but Antioxidants Could Provide Answer

MRV Research

The risk of developing cancer increases with age as accumulated damage to the cells and chronic inflammation arise over time. In a new study published in Nature, an international team of researchers led by The Wistar Institute demonstrated that aged melanoma cells behave in a different manner than younger cells, and that antioxidants could be a potential treatment strategy for older melanoma patients. The study is titled “sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.”

Read More
MRV News
Melanoma News
Archive
Menu